Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Dividends Paid - Preferred Dividends Paid - Preferred Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Lifecore Biomedical, Inc. \De\ (LFCR) Other financing activities (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Other financing activities over the past 14 years, most recently at $107000.0 for Q2 2024.

For Q2 2024, Other financing activities fell 95.51% year-over-year to $107000.0; the TTM value through May 2025 reached $6.2 million, changed 0.0%, while the annual FY2025 figure was $435000.0, 88.31% up from the prior year.
Other financing activities for Q2 2024 was $107000.0 at Lifecore Biomedical, Inc. \De\, down from $2.4 million in the prior quarter.
Over five years, Other financing activities peaked at $9.6 million in Q1 2021 and troughed at -$512000.0 in Q4 2020.
A 5-year average of $1.7 million and a median of $652000.0 in 2022 define the central range for Other financing activities.
Biggest five-year swings in Other financing activities: crashed 166.84% in 2020 and later skyrocketed 9816.22% in 2023.
Year by year, Other financing activities stood at -$512000.0 in 2020, then soared by 125.78% to $132000.0 in 2021, then skyrocketed by 393.94% to $652000.0 in 2022, then skyrocketed by 265.18% to $2.4 million in 2023, then crashed by 95.51% to $107000.0 in 2024.
Business Quant data shows Other financing activities for LFCR at $107000.0 in Q2 2024, $2.4 million in Q2 2023, and $3.7 million in Q1 2023.